

## AXIRON NET SALES, QUARTER TO 31 DECEMBER 2015

---

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US\$41.6 million in its financial results for the quarter ending 31 December 2015, up from US\$41.4 million for the previous quarter to 30 September, 2015.

Axiron net sales for the calendar year 2015 are shown in the following table:

Q1 2015	Q2 2015	Q3 2015	Q4 2015	Total 2015
US\$39.1m	US\$32.4m	US\$41.4m	US\$41.6m	US\$154.5m

Net sales for the second half of 2015 increased 16.1%, when compared to the first half of 2015, and are comparable to the second half of 2014. Axiron held a 2015 exit market share of 14.4%, again comparable to 2014.

### For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

### About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)

